Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Estradiol · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Estradiol treatment | EXPERIMENTAL | Estradiol 6 mg daily for 7-14 days |
| Name | Type | Description |
|---|---|---|
| Estradiol | DRUG | Eligible participants will take 2 mg Estradiol 3 times daily for 7-14 days pre-surgery. |
Inclusion Criteria: * Female gender * Estrogen receptor positive (ER+) breast cancer * HER2 negative breast cancer * Post-menopausal by greater than 5 years * No previous hormonal replacement therapy * Low to intermediate histologic grade * ECOG Performance status of 0 of 1 * Adequate hematological...
Estradiol is being studied as a treatment for Estrogen Receptor Positive Breast Cancer. It is an investigational small molecule in Phase 2 clinical development. The drug is being evaluated in a single-arm, open-label trial to determine whether estrogen can slow the growth of certain ER-positive breast cancers.
Estradiol targets the estrogen receptor, which is present in estrogen receptor positive breast cancer cells. By interacting with this receptor, the drug is intended to potentially slow the growth of these cancer cells. The ongoing clinical trial is specifically designed to assess this effect in postmenopausal women.
Estradiol is being developed by Avalon GloboCare Corp., a biopharmaceutical company. The company is conducting a Phase 2 clinical trial of Estradiol for Estrogen Receptor Positive Breast Cancer. Avalon GloboCare Corp. is publicly traded under the ticker symbol ALBT.
Estradiol is currently in Phase 2 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The ongoing Phase 2 trial is active but not recruiting participants, with a planned enrollment of 19 patients.
Estradiol is being evaluated in a Phase 2 clinical trial with the identifier NCT02238808. The trial is titled 'A Study to See Whether Estrogen Can Slow the Growth of Some ER Positive Breast Cancers.' It is an uncontrolled, open-label study conducted in Canada, enrolling women aged 55 years and older.
Yes, Estradiol is a form of estrogen. It is a naturally occurring estrogen hormone being repurposed as a potential cancer therapy. In the context of this clinical trial, Estradiol is being investigated for its ability to slow the growth of estrogen receptor positive breast cancer cells.